Searchable abstracts of presentations at key conferences in endocrinology

ea0051p049 | Pituitary and growth | BSPED2017

Comparison of insulin tolerance test to arginine test for the diagnosis of growth hormone deficiency in children

Sakka Sophia , Casey Angela , Follows Rebecca , Dias Renuka

Background: Growth hormone (GH) stimulation testing is necessary for the diagnosis of growth hormone deficiency (GHD). Insulin tolerance test (ITT) has been considered the gold standard for evaluating GHD in adults. However, it carries a risk of rare but severe adverse effects secondary to hypoglycaemia and is therefore avoided in many centres. There is no consensus for the first test in children.Aim: Audit to compare ITT to Arginine test as a first line...

ea0039ep104 | Pituitary and growth | BSPED2015

Overcoming the need for a second test: an evaluation of anthropometric, biochemical, and radiological parameters in the diagnosis of GH deficiency

Ali Muzzammil , Casey Angela , Kirk Jeremy , Dias Renuka

Background: The investigation of short stature includes evaluation of a number of clinical, radiological, and biochemical factors. This often includes dynamic function testing to rule out abnormalities of the hypothalamic–pituitary axis to rule out GH deficiency (GHD). NICE guidance advises that two GH stimulation tests demonstrating subnormal GH peak <6.7 μg/ml (20 mU/l) is required to confirm the diagnosis of GHD.Objectives: To interrogat...

ea0033oc1.1 | Oral Communications 1 | BSPED2013

GH testing: reducing the need for a second test for the diagnosis of GH deficiency

Juma Zain , Casey Angela , Prior Jullia , Kirk Jeremy , Dias Renuka

Background: The diagnosis of isolated GH deficiency (IGHD) is based on multiple factors: clinical, radiological and biochemical along with suboptimal peak GH levels demonstrated on dynamic testing. Recent guidance from the National Institute of Clinical Excellence (NICE; UK; 2010) advises that two GH stimulation tests must demonstrate a subnormal GH peak <6.7 μg/l (20 mU/l) to confirm the diagnosis of IGHD. In our centre, three different GH provocation tests are used:...

ea0033p70 | (1) | BSPED2013

Growth hormone device change-over; is it beneficial?

Ayuk Loveline , Casey Angela , Prior Julia , Kirk Jeremy

Recombinant growth hormone (GH) administration uses several different injection devices. Despite offering free patient choice at GH therapy start, ~20% of our patients subsequently change GH device.Objective: To investigate reasons for GH device change, and evaluate the effect on adherence, height velocity standard deviation (HVSDS), and insulin-like growth factor-1 (IGF1).Method: Retrospective study of extracted growth data and la...

ea0027p7 | (1) | BSPED2011

Effect of patient choice and hospital tracking on short term growth in children treated with GH therapy

Atapattu Navoda , Casey Angela , Prior Julia , Howarth Isobel , Zia Rani , Akhtar Saeeda , Davies Paul , Kirk Jeremy

Introduction: Most (89%) UK units offer some form of free patient choice for new paediatric patients commencing GH therapy. Initial data indicates that patient choice improves adherence, resulting in improved growth (height velocity) short-term.Objective: To compare outcome measures between patients offered free choice and/or hospital supply (including home services and adherence tracking assessed using ampoule counting) with GH therapy with those who di...